A 48-year-old man with a history of hypertension came to the emergency department in March 2020, during the COVID-19 bud in Madrid.
He reported fever (at 39 °C) several days before admission, together with chest pain and dyspnea.
He noticed the sudden appearance of slightly pruritic skin lesions 3 days after the onset of fever.
He had not taken any medication during the year preceding this episode.
Physical examination revealed confluent erythematous macules,▁papules and petechiae in a symmetrical periflexural distribution with involvement of the buttocks, the popliteal fossae.
It should be noted a notable absence of lesions in the crural folds.
There were no acral or mucosal lesions.
The exanthema consisted of erythematous macules,▁papules and petechiae that affected the buttocks, popliteal fossae and anterior thighs.
The chest X-rays showed a ground glass opacity in both lung fields, consistent with pneumonia a
A complete blood count revealed a lymphocyte count of 750/μL (reference, 1000-4500/μL) reference (range, 0-0.56)
Thrombocyte count and coagulation parameters were normal.
Serological tests were negative for HIV, hepatitis B virus, hepatitis C virus and parvovirus B19.
Real-time RT-PCR results from nasopharyngeal swabs were positive for SARS-CoV-2.
A biopsy sample of 5 mm saccao-cattles from the left buttock showed a superficial perivascular▁lymphocytic infiltrate with abundant erythrocyte extravasation and focal papillary oedema, together with focal parakeratosis and dysplastic cells.
No characteristics of thrombotic vasculopathy were observed.
The patient was hospitalized and was treated with hydroxychloroquine (200 mg twice daily), lopinavir/ritonavir (200 mg/50 mg twice daily) and azithromycin (250 mg/d).
The patient continued to receive regular medication for hypertension, telmisartan.
The exanthema was treated with betamethasone cream 0.05% dexamethasone twice daily and loratadine (10 mg/d).
Skin lesions disappeared after 5 days.
The patient was discharged after 12 days.
